• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Ott MP: Neuropathy progression in Charcot-Marie-Tooth illness form 1A. Neurology 2008, 70:378?eighty three. 119. Garcia A, Combarros O, Calleja J, Berciano J: Charcot-Marie-Tooth sickness form 1A with 17p duplication in infancy and early childhood: a longitudinal medical and electrophysiologic Lenvatinib review. Neurology 1998, 50:1061?067. a hundred and twenty. Padua L, Pareyson D, Aprile I, Cavallaro T, Quattrone A, Rizzuto N, Vita G, Tonali P, Schenone A: Normal record of CMT1A including QoL: A 2-year potential examine. Neuromuscul Disord 2008, 18:199?03. 121. Manfioletti G, Ruaro ME, Del Sal G, Philipson L, Schneider C: A progress arrest-specific (fuel) gene codes for just a membrane protein. Mol Mobile Biol 1990, ten:2924?930. 122. Choi BO, Koo SK, Park MH, Rhee H, Yang SJ, Choi KG, Jung SC, Kim HS, Hyun YS, Nakhro K, Lee HJ, Woo HM, Chung KW: Exome sequencing is surely an effective software for genetic screening of Charcot-Marie-Tooth disease. Hum Mutat 2012, 33:1610?615. 123. Kohl B, Groh J, Wessig C, Wiendl H, Kroner A, Martini R: Deficiency of proof for your pathogenic position of T-lymphocytes within an animal model for CharcotMarie-Tooth disease 1A. Neurobiol Dis 2010, 38:78?4. 124. Kohl B, Fischer S, Groh J, Wessig C, Martini R: MCP-1/CCL2 Modifies Axon Houses in the PMP22-Overexpressing Mouse Product for Charcot-MarieTooth 1A Neuropathy. Am J Pathol 2010, 176:1390?399. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12711626 125. Ramaglia V, Tannemaat MR, De Kok M, Wolterman R, Vigar MA, King RH, Morgan BP, Baas F: Enhance inhibition accelerates regeneration within a design of peripheral nerve injury. Mol Immunol 2009, forty seven:302?09. 126. Ramaglia V, Wolterman R, De Kok M, Vigar MA, Wagenaar-Bos I, King RH, Morgan BP, Baas F: Soluble complement receptor 1 safeguards the peripheral nerve from early axon decline following harm. Am J Pathol 2008, 172:1043?052. 127. Sereda MW, Meyer Zu Horste G, Suter U, Uzma N, Nave KA: Therapeutic administration of progesterone antagonist in the product of Charcot-MarieTooth ailment (CMT-1A). Nat Med 2003, nine:1533?537. 128. Meyer Zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW: Antiprogesterone treatment uncouples axonal loss from demyelination in a very transgenic rat product of CMT1A neuropathy. Ann Neurol 2007, 61:sixty one?2. 129. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M: Ascorbic acid cure corrects the phenotype of a mouse model of Charcot-Marie-Tooth illness. Nat Med 2004, 10:396?01. 130. Verhamme C, De Haan RJ, Vermeulen M, Baas F, De Visser M, Van Schaik IN: Oral superior dose ascorbic acid cure for 1 12 months in youthful CMT1A patients: a randomised, double-blind, placebo-controlled period II trial. BMC Med 2009, 7:70. 131. Micallef J, Attarian S, Dubourg O, Gonnaud PM, Hogrel JY, Stojkovic T, Bernard R, Jouve E, Pitel S, Vacherot F, Remec JF, Jomir L, Azabou E, AlMoussawi M, Lefebvre MN, Attolini L, Yaici S, Tanesse D, Fontes M, Pouget J, Blin O: Result of ascorbic acid in people with Charcot-Marie-Tooth illness sort 1A: a multicentre, randomised, double-blind, placebocontrolled demo. Lancet Neurol 2009, 8:1103?110. 132. Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, Ryan MM: Ascorbic acid for Charcot-Marie-Tooth illness variety 1A in young children: a randomised, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/9547713 double-blind, placebo-controlled, protection and efficacy trial. Lancet Neurol 2009, eight:537?44. 133. Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laur?M, Radice D, Calabrese D, Hughes RA, Solari A: Asc.